Hello Team,

We recently received word from the client that (company) will soon need to attest to the COIVD-19 vaccination status of our employees on the contract.

The client requests that all employees on this contract be fully vaccinated by November 22, 2021.

At this time, I just wanted to notify you that we received this communication. I will be reaching out to our employees in the following weeks as more information is provided to us.

I know some of you may have some questions or concerns. Please do not hesitate to reach out to me. I am more than happy to discuss your questions and concerns.

If you are not yet vaccinated, below is a timeline that (client) provided to meet their vaccination deadline according to the type of vaccine.

• The Pfizer-BioNTech/COMIRNATY COVID-19 vaccine is approved by the FDA and is the only mandatory COVID-19 vaccine. Individuals should get their second shot 3 weeks (or 21 days) after the first. This means that in order for Federal employees to meet a November 22 deadline, they should receive their first vaccination no later than October 18, and their second dose no later than November 8.

• The Moderna COVID-19 vaccine, is authorized for voluntary use. Individuals should get their second shot 4 weeks (or 28 days) after their first. This means that in order for Federal employees to meet a November 22 deadline, they should receive their first vaccination dose no later than October 11, and their second dose no later than November 8.

• The Johnson & Johnson/Janssen (J&J) COVID-19 vaccine is also authorized for voluntary use. Because J&J only has one shot, Federal employees must get that dose by November 8, in order to meet a November 22 deadline to be fully vaccinated.

• If using vaccines on the World Health Organization (WHO) Emergency Use Listing (EUL) or approved for use in a clinical trial, ensure adequate time is allotted for the respective dosing protocols to meet the 22 November suspense.

The Center for Disease Control (CDC) has found the available COVID vaccinations are safe and extremely effective in precluding most infections and in minimizing the severity of the few breakthrough infections.